<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="1" pm="."><plain>This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line (WSU-FSCCL) and cell isolated from <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC50) of 109 nM and <z:mp ids='MP_0000329'>decreased cell number</z:mp> of fresh <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain>ApoG2 activated caspases-9, -3, and -8, and the cleavage of Poly (<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase (PARP) and <z:mpath ids='MPATH_3'>Apoptosis</z:mpath> Inducing Factor (AIF) </plain></SENT>
<SENT sid="4" pm="."><plain>In the WSU-FSCCL-<z:mp ids='MP_0002536'>SCID</z:mp> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, ApoG2 showed a significant anti-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice </plain></SENT>
<SENT sid="5" pm="."><plain>These studies suggest that ApoG2 can be an effective therapeutic agent against FL </plain></SENT>
</text></document>